Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinibReport as inadecuate




Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib - Download this document for free, or read online. Document in PDF available to download.

Medical Oncology

, Volume 28, Issue 4, pp 1527–1529

First Online: 10 August 2010Received: 18 June 2010Accepted: 24 July 2010

Abstract

A 70-year-old man with metastatic renal cell carcinoma developed progressive liver metastases after 8 weeks of treatment with the multitargeted tyrosine kinase inhibitor TKI sunitinib. He then participated in the phase III placebo-controlled clinical trial of the oral mammalian target of rapamycin mTOR inhibitor everolimus, initially randomized to placebo but had disease progression after 3 months and crossed over to everolimus at time of unblinding. The patient had stable disease after 8 weeks two cycles of everolimus that was maintained until 28 months of therapy, at which time the patient had achieved a partial response. This case illustrates the potential for patients with metastatic renal cell carcinoma, a malignancy with historically poor prognosis, to derive long-term benefit from everolimus when used in a manner consistent with its approved indication after TKI therapy with sunitinib or sorafenib.

KeywordsRenal cell carcinoma Kidney cancer Everolimus mTOR Sunitinib Metastatic  Download fulltext PDF



Author: Ana M. Molina - Michelle S. Ginsberg - Robert J. Motzer

Source: https://link.springer.com/







Related documents